Autologous collagen II-reactive T-cell clones (CII-reactive T-cells) (CII-reactive T-cells)

Autologous collagen II-reactive T-cell clones are a specific subset of CD4+ T-lymphocytes that recognize type II collagen (CII), a major structural protein in joint cartilage. In patients with rheumatoid arthritis (RA), these T-cells are thought to play a central role in the pathogenesis of the disease by initiating and sustaining an autoimmune attack against the joints (Zhang et al., 1996, Journal of Immunology). These clones are the primary focus of T-cell vaccination (TCV), an experimental immunotherapy where the patient's own CII-reactive T-cells are isolated from blood or synovial fluid, expanded in vitro, and then attenuated via irradiation before being re-injected (Van Laar et al., 2000, Arthritis & Rheumatism). The therapeutic goal is to stimulate the patient's immune system to produce regulatory anti-idiotypic T-cells that specifically target the T-cell receptors (TCRs) of the pathogenic collagen-reactive clones, thereby suppressing the autoimmune response (Moreland et al., 1998, Arthritis & Rheumatism). While this approach offers a highly specific method of immune modulation, its clinical application has been challenged by the high cost and technical difficulty of producing personalized cell therapies compared to standardized monoclonal antibodies.

Other names

Collagen type II-specific T-lymphocytesCII-specific T-cell clonesAutologous T-cell vaccineCII-reactive T-cells

Induction of anti-idiotypic and anti-ergotypic immune responses to suppress or deplete pathogenic collagen-reactive T-cells.